Education
About Us
Working with TipRanks
Follow Us
Csl Ltd (CSLLY)
:CSLLY
Top Page
CSL
(OTC:CSLLY)
Rating:75Outperform
Price Target:
$89.00
▲(10.52%Upside)
CSL (CSLLY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$78.86B
Dividend Yield1.47%
Average Volume (3M)2.33K
Price to Earnings (P/E)28.8
Beta (1Y)0.45
Revenue Growth7.60%
EPS Growth9.47%
CountryUS
Employees32,698
SectorHealthcare
Sector Strength44
IndustryBiotechnology
Share Statistics
EPS (TTM)2.07
Shares Outstanding968,424,260
10 Day Avg. Volume2,476
30 Day Avg. Volume2,335
Financial Highlights & Ratios
PEG Ratio46.13
Price to Book (P/B)4.26
Price to Sales (P/S)0.00
P/FCF Ratio42.14
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit11.99
Enterprise Value/Ebitda4.78
Forecast
1Y Price Target
$86.00Price Target Upside6.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
CSL Business Overview & Revenue Model
Company DescriptionCSL Limited (CSLLY) is a global biotechnology company that specializes in the development and manufacture of innovative biotherapies and influenza vaccines. It operates through two main segments: CSL Behring and Seqirus. CSL Behring focuses on providing life-saving treatments for people with rare and serious diseases through its plasma-derived therapies, recombinant therapies, and related products. Seqirus, on the other hand, is one of the largest influenza vaccine companies in the world, supplying vaccines to both public and private sectors globally.
How the Company Makes MoneyCSL Limited generates revenue primarily through the sale of its biotherapeutic and vaccine products. Its major revenue streams include plasma-derived therapies such as immunoglobulins, albumin, and coagulation factors that treat conditions like hemophilia and immune deficiencies. Additionally, its Seqirus segment contributes significantly to revenue through the production and distribution of influenza vaccines. The company benefits from strategic partnerships and collaborations that enhance its research and development capabilities, allowing it to innovate and expand its product offerings. CSL's earnings are also influenced by its extensive global distribution network and its ability to leverage economies of scale in manufacturing.
CSL Earnings Call Summary
Earnings Call Date:Feb 11, 2025
(Q2-2025)
| % Change Since: 0.42%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
The earnings call presented a balanced view of CSL's financial performance. Strong growth in CSL Behring and CSL Vifor, along with successful regulatory milestones, were offset by challenges in CSL Seqirus due to declining vaccination rates and increased competition in Europe. Overall, the call reflects a stable performance with a positive outlook for revenue growth.Q2-2025 Updates
Positive Updates
Strong Revenue Growth
CSL reported revenue of AUD 8.5 billion, up 5% at constant currency with NPATA expected to grow by 10% to 13% for fiscal year 2025.
CSL Behring Performance
The CSL Behring business achieved a strong growth of 10%, driven by a 15% increase in the Ig franchise and a 9% increase in the albumin portfolio, with gross margin up 170 basis points.
CSL Vifor Growth
CSL Vifor's revenue increased by 6%, with FERINJECT showing volume growth of 6% in Europe and solid performance in nephrology segment.
Rika Platform Rollout
The rollout of Rika plasmapheresis machines is well advanced with 220 centers operating and iNomi technology implemented, increasing donor yields by around 10%.
Positive Regulatory Milestones
Garadacimab branded as ANDEMBRY received regulatory approvals in Australia and the UK, with a positive CHMP recommendation in Europe and US FDA acceptance.
Negative Updates
CSL Seqirus Revenue Decline
CSL Seqirus experienced a 9% decline in revenue due to a significant drop in influenza immunization rates in the US, particularly in the 18 to 64 age cohort.
KCENTRA Sales Decline
Specialty products saw a decline of 5%, with KCENTRA sales down 20% due to the loss of a substantial contract.
Competitive Pressures in Europe
The presence of generic competition in Europe led to pricing pressures in the iron portfolio, affecting margins despite volume growth.
Increased General and Admin Costs
General and admin costs increased by 27% compared to the prior period, largely due to one-off project costs.
Company Guidance
In the first half of fiscal year 2025, CSL Limited reported solid financial results, reaffirming their guidance for NPATA growth of 10% to 13% for the fiscal year. Revenue increased by 5% at constant currency to AUD 8.5 billion, with NPATA reaching AUD 2.1 billion, up 5%. The net profit after tax was AUD 2 billion, reflecting a 7% increase. The CSL Behring business grew by 10%, driven primarily by a 15% increase in their Ig franchise and a 9% growth in their albumin portfolio, particularly in China. Despite challenges in the U.S. market affecting CSL Seqirus, the company secured several pandemic tenders for avian flu, with most revenue expected in the second half. CSL Vifor also showed a 6% revenue increase, supported by strong performances in iron and nephrology. CSL Behring's gross margin improved by 170 basis points, attributed to efficiency enhancements and the rollout of Rika plasmapheresis machines. The company's annual guidance includes expected revenue growth of 5% to 7% and NPATA between AUD 3.2 billion to AUD 3.3 billion at constant currency, marking a 10% to 13% growth.CSL Financial Statement Overview
Summary
CSL showcases strong financial health with significant revenue growth and stable profitability. The balance sheet is sound with a robust equity base, though leverage remains a concern. Cash flow generation is healthy, supporting future investments. Overall, CSL's financial stability and growth trajectory are solid.Income Statement
CSL has demonstrated strong revenue growth with a remarkable increase from $5.95B in 2019 to $14.69B in 2024. The gross profit margin has consistently been healthy, maintaining above 50% over the years, while the net profit margin has shown resilience, peaking at 18% in the most recent year. EBIT and EBITDA margins indicate solid operational efficiency. The company's ability to grow revenues and maintain stable margins underscores its competitive positioning in the biotechnology industry.85
Very Positive
Balance Sheet
The balance sheet reflects a robust equity base with stockholders' equity increasing considerably to $17.33B. The debt-to-equity ratio is manageable, though leverage has increased, which may pose some financial risks if earnings do not continue to grow. The equity ratio has shown stability, supporting the company's capacity to leverage its assets effectively. Overall, CSL's balance sheet is strong but could benefit from reduced leverage.78
Positive
Cash Flow
CSL's cash flow statement reveals a healthy operating cash flow, consistently growing over the years. The free cash flow has also increased, indicating effective capital expenditure management. The operating cash flow to net income ratio suggests that cash generation is well-aligned with reported earnings, improving financial stability. The company is in a solid cash position to support its growth initiatives.82
Very Positive
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.69B | 13.17B | 10.49B | 10.33B | 9.41B |
| Gross Profit | 7.56B | 9.47B | 5.66B | 5.74B | 5.28B |
| EBITDA | 4.73B | 3.90B | 3.46B | 2.72B | 2.18B |
| Net Income | 2.64B | 2.19B | 3.11B | 2.39B | 2.17B |
Balance Sheet | |||||
| Total Assets | 38.02B | 54.43B | 41.22B | 18.16B | 15.46B |
| Cash, Cash Equivalents and Short-Term Investments | 1.66B | 2.33B | 15.18B | 1.81B | 1.19B |
| Total Debt | 12.18B | 18.37B | 14.04B | 5.81B | 5.99B |
| Total Liabilities | 18.62B | 27.65B | 20.02B | 9.74B | 8.94B |
| Stockholders Equity | 17.33B | 23.72B | 21.20B | 8.38B | 6.53B |
Cash Flow | |||||
| Free Cash Flow | 1.51B | 1.35B | 1.90B | 1.97B | 1.16B |
| Operating Cash Flow | 2.76B | 3.87B | 3.62B | 3.65B | 2.57B |
| Investing Cash Flow | -1.26B | -17.61B | -2.26B | -1.68B | -1.41B |
| Financing Cash Flow | -1.28B | 677.92M | 10.58B | -1.41B | -664.30M |
CSL Technical Analysis
Positive
80.53
Price Trends
78.82
Positive
78.84
Positive
84.48
Negative
Market Momentum
0.49
Negative
55.86
Neutral
63.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSLLY, the sentiment is Positive. The current price of 80.53 is above the 20-day moving average (MA) of 78.89, above the 50-day MA of 78.82, and below the 200-day MA of 84.48, indicating a neutral trend. The MACD of 0.49 indicates Negative momentum. The RSI at 55.86 is Neutral, neither overbought nor oversold. The STOCH value of 63.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CSLLY.
CSL Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $34.23B | 41.61 | 17.33% | ― | 78.01% | ― | |
75 Outperform | $78.86B | 28.80 | 15.36% | 1.47% | 7.60% | 9.47% | |
74 Outperform | $59.16B | 13.95 | 15.96% | 0.64% | 7.52% | 15.65% | |
66 Neutral | $40.57B | ― | -414.62% | ― | 17.21% | 21.16% | |
61 Neutral | $119.21B | ― | -5.64% | ― | 8.55% | -124.45% | |
58 Neutral | $26.60B | ― | -3.87% | ― | 0.58% | -764.64% | |
52 Neutral | $7.47B | -0.04 | -63.86% | 2.34% | 16.17% | 0.25% |
* Healthcare Sector Average
Performance Comparison
CSLLY
CSL
80.53
-22.32
-21.70%
ALNY
Alnylam Pharma
324.69
86.86
36.52%
REGN
Regeneron
550.00
-510.67
-48.15%
VRTX
Vertex Pharmaceuticals
463.27
-28.30
-5.76%
ARGX
Argenx Se
572.71
101.39
21.51%
BNTX
BioNTech SE
111.04
25.58
29.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.